Aquestive Therapeutics releases Anaphylm human factors, clinical study presentation materials

• Aquestive Therapeutics published supplemental materials on human factors and clinical results for its Anaphylm (dibutepinephrine) sublingual film program.
• Resubmission human factors study in 105 untrained participants showed fewer use issues versus the original NDA study, including median open time cut to 3 seconds.
• PK study in healthy subjects showed self-administration comparable to clinician administration, with geometric mean Cmax 391.7 pg/mL vs 357.6 pg/mL.
• Purposeful top-of-tongue misplacement produced lower exposure, with geometric mean Cmax 112.7 pg/mL, while showing a clinically meaningful pharmacodynamic response.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.